Cancer
More Than Half Of Relapsed CLL Patients Respond To Two Biologics With Chemotherapy
19 years, 4 months ago
8040
0
Posted on Dec 17, 2004, 3 a.m.
By Bill Freeman
Combining two biologic agents with chemotherapy forms a potent drug regimen that is showing promise in treating patients who have relapsed with the most common kind of leukemia, chronic lymphocytic leukemia (CLL), researchers from The University of Texas M. D. Anderson Cancer Center report at the annual meeting of the American Society of Hematology (ASH).
Combining two biologic agents with chemotherapy forms a potent drug regimen that is showing promise in treating patients who have relapsed with the most common kind of leukemia, chronic lymphocytic leukemia (CLL), researchers from The University of Texas M. D. Anderson Cancer Center report at the annual meeting of the American Society of Hematology (ASH).
http://www.sciencedaily.com/releases/2004/12/041206205625.htm
http://www.sciencedaily.com/releases/2004/12/041206205625.htm
